- Recipharm has secured two new contracts involving Blow-Fill-Seal (BFS) clinical production for ophthalmic drug development.
- The company will supply material for both a Phase 1 study and a Phase 2/3 programme, leveraging its BFS platform for small-scale cGMP batches.
Recipharm, a global contract development and manufacturing organisation (CDMO), has signed two new development agreements to support clinical production using its Blow-Fill-Seal (BFS) platform. The contracts expand Recipharm’s footprint in ophthalmology, covering both biologic and small molecule products.
The first agreement is with a top-five global ophthalmic company for a Phase 1 trial. It will use Recipharm’s Lab+ pilot scale platform to deliver small-volume, cGMP-compliant clinical trial material (CTM). The second involves a Phase 2/3 ophthalmic suspension programme with a global biotech, also using Recipharm’s BFS expertise.
The BFS technology, which forms, fills and seals containers in a sterile, closed system, offers clear benefits in early-stage manufacturing. With minimum batch sizes starting at 200 ml, Recipharm estimates that BFS can save over 90% of API compared to other platforms—an advantage in early clinical development.
Commenting on the new contracts, Vincenza Pironti, Head of Business Development at Recipharm, said: “These partnerships highlight Recipharm’s position as a trusted partner from early clinical development through to commercialisation.”
The company’s BFS capabilities are part of a broader offering that includes pre-filled syringes, oral solid technologies and full product development services. Recipharm continues to invest in BFS to offer flexible, rapid, and integrated CDMO solutions across clinical phases and into commercial supply.
Stay ahead of trends and best practices
